EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Guests file in to the Novartis Institutes for Biomedical Research for some pre-event schmoozing.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Martin Seidel, NIBR’s global head of strategic alliances, gets things underway.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

From left: Peter Barrett, Tom Hughes, and Bruce Booth share a laugh recounting Hughes’ initial disinterest in running Zafgen.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Never forget your notepad at one of these events, you just might learn something.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Robert Gould talks being pitched about Epizyme: “it was a fundamental area of biology, a fundamental opportunity, particularly in the field of cancer.” He was named the company’s CEO in 2010.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Not a seat in the house as Bay City Capital’s Carl Goldfischer talks the pros and cons of pushing for an IPO or a sale.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Profound thoughts, indeed.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Though sporting the best shoes in the house, Kevin Starr (r.) gives more than just fashion lessons. Sage CEO Jeff Jonas looks on.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Jonas had the crowd rolling recounting his first pitch from Sage, and the “farkakt indications,” it first intended to pursue.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Let the post-event mingling begin.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Only the healthiest grub for our attendees. This is a healthcare event after all.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Why would Epizyme go public? I mean come on, it’s way easier to sell.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Is this a drone strike? No, our photographer will find you from any angle.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

The business card exchange; an event tradition.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Connections are made over drinks and veggies.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

It’s only a matter of time before someone spots our camera man.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Whatever you do, DON’T try and go public without testing the waters first.

Boston's Life Science Disruptors

Boston's Life Science Disruptors

Special thanks to all of our attendees for making this event a success. We’ll see you again for the Healthcare Summit in November.

Xconomy Boston — 

How do you pull off a successful biotech IPO? With patience, preparation, and no fear of failure.

Last week, I recapped our latest biotech event, “Boston’s Life Science Disruptors.” Attendees at the Novartis Institutes for Biomedical Research got a behind-the-scenes look at the ups and downs faced by three local biotechs—Zafgen, Epizyme, and Sage Therapeutics—on their way to successful Nasdaq debuts.

Today, I’m circling back with a slideshow look at the proceedings, with a tip of the cap to Tyler Trahan for the photos.

Once again, thanks to our speakers, our event host Novartis and our sponsors BDO, Cubist Pharmaceuticals, Health Advances, Icon, Johnson & Johnson Innovation, and Mintz Levin Cohn Ferris Glovsky and Popeo. With that, on with the slideshow.

By posting a comment, you agree to our terms and conditions.